QTTB
Q32 Bio Inc · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website q32bio.com
- Employees(FY) 37
- ISIN US7469641051
Performance
-15.53%
1W
-87.66%
1M
-92.39%
3M
-80.26%
6M
-67.2%
YTD
-63.74%
1Y
Profile
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to rebalance immunity in autoimmune and inflammatory diseases. Its products in the pipeline include ADX-914, a human anti-IL-7R antibody that re-regulates adaptive immune function, and ADX-097, which has in vivo biodistribution to affected tissues and organs, durable tissue pharmacokinetics and pharmacodynamics, and robust in vivo efficacy. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was incorporated in 2017 and is based in Waltham, Massachusetts.
Technical Analysis of QTTB 2024-12-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-11 18:45
Q32 Bio price target lowered to $20 from $80 at Oppenheimer(Yahoo Finance)
- 2024-12-11 03:11
- 2024-12-10 20:42
- 2024-12-10 03:05
- 2024-11-07 06:59
- 2024-11-06 17:59
- 2024-11-05 06:59
- 2024-11-04 17:59
- 2024-10-14 06:59
- 2024-10-13 18:59
- 2024-08-29 06:59
- 2024-08-28 18:59
- 2024-07-09 06:59
- 2024-07-08 18:59
- 2024-07-01 06:59
Q32 Bio Joins Russell 3000® Index(PR Newswire)
- 2024-06-30 18:59
Q32 Bio Joins Russell 3000 Index(Prnewswire)
- 2024-06-27 07:05
- 2024-05-09 06:59
- 2024-05-09 01:56
QTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024(Investorplace)
- 2024-05-08 18:59
- 2024-04-02 19:00
- 2024-03-18 04:30
- 2024-03-15 09:52
- 2024-02-29 21:48
- 2024-01-26 23:10
- 2024-01-03 03:08
- 2023-11-16 17:40
Q32 Bio to merge with Homology Medicines(Pharmaceutical-business-review)
- 2023-11-15 23:18
Homology enters reverse merger with Q32 Bio(Yahoo Finance)
- 2023-11-15 18:05
- 2023-11-14 04:02
Homology Medicines: Q3 Earnings Snapshot(Yahoo Finance)
Page 1 of 5
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.